Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 19, 2009

Scripps Research Institute to Use ISCO’s Parthenogenetic Stem Cells

  • International Stem Cell (ISCO) is collaborating with stem cell researcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute to study parthenogenetic stem cells and potentially therapeutic cells that can be derived from them. Dr. Loring will use the parthenogenetic cell lines in her quest to understand the genetic and epigenetic processes that control stem cells.

    ISCO scientists have derived a type of cell found in the human eye from parthenogenetic stem cells that may have application in the treatment of a common eye disease called macular degeneration. Dr. Loring and ISCO will study these cells as part of the collaboration.

    ISCO has developed a process for creating human stem cells from unfertilized human eggs. These parthenogenetic stem cells have the medical advantage of allowing immune-matching to large segments of the population and the ethical advantage of not requiring the use of human embryos, according to the company.

    This study is a further expansion of ISCO’s mission to generate data necessary to understand these cells and move them closer to the clinic.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »